Reed Jobs’ $350M Fund Aims to Turn Cancer into a Chronic Disease

The personal tragedy of losing his father to pancreatic cancer at age 12 spurred Reed Jobs to dedicate his career to combating the disease. His father, Apple founder Steve Jobs, succumbed to the illness eight years after his diagnosis at the age of 56. This early experience fueled a commitment to funding innovative cancer research and treatment.

A New Venture Focused on Oncology

Driven by this personal connection, Jobs has become a significant investor in healthcare companies. He initially focused his efforts at Emerson Collective, the impact investment and philanthropy group founded by his mother, Laurene Powell Jobs, whose net worth is estimated at $13.5 billion. In 2023, he launched Yosemite, a firm named after the national park where his parents married, raising an initial fund of $263 million.

Did You Know? Yosemite has already invested in approximately 20 companies focused on cancer treatment and related fields.

Expanding Investment and Partnerships

Yosemite recently secured over $200 million towards a second fund, aiming for a total size of $350 million. This new fund has attracted substantial investment from prominent players in the biotech and healthcare sectors, including Amgen, Memorial Sloan Kettering, MIT, and venture capitalist John Doerr. Powell Jobs is also contributing to the fund through Emerson, and Jobs himself is a general partner with a personal investment.

Yosemite’s investment strategy encompasses a broad range of cancers, from more treatable forms like colon cancer to the particularly aggressive and often fatal pancreatic cancer. The firm is actively seeking companies developing diverse solutions, recognizing that some cancers will remain challenging for the foreseeable future. Jobs believes that early detection, targeted therapies, and continuous monitoring will be key to reducing cancer mortality rates.

A Unique Approach to Venture Capital

While Yosemite operates as a venture capital firm, it distinguishes itself through a hybrid model. In addition to traditional investments, the firm provides grants to scientists, offering support without requiring equity. This approach aims to bridge the “Valley of Death” – the gap between scientific discovery and investor confidence – and is particularly important given potential cuts to federal science funding.

Expert Insight: Jobs’ willingness to provide grants alongside investments demonstrates a long-term commitment to fostering innovation in cancer research, recognizing that breakthroughs often require sustained support beyond the typical venture capital timeline.

Companies like Azalea Therapeutics, spun out of Nobel Prize winner Jennifer Doudna’s lab at UC Berkeley, have benefited from Yosemite’s early-stage grants. Azalea is pioneering a gene therapy technique that modifies cells within the body, rather than requiring their removal. Another investment is Chai Discovery, a company utilizing AI to design proteins for new drug development, achieving a $1.3 billion valuation after a $130 million funding round and a partnership with Eli Lilly.

Looking Ahead

Yosemite currently manages over $1 billion in assets, including funds for endowments, hospitals, and foundations. While relatively small compared to venture capital giants, the firm is gaining prominence in healthcare, particularly in oncology. Jobs anticipates that the new fund will invest in around 25 companies, with a focus on areas like radiopharmaceuticals and AI-driven drug discovery and healthcare efficiency. He also highlights the potential of cancer vaccines, both for prevention and treatment.

Frequently Asked Questions

What motivated Reed Jobs to enter the field of cancer research investment?

Reed Jobs’ motivation stems from the loss of his father, Apple founder Steve Jobs, to pancreatic cancer, which he witnessed as a 12-year-old.

What is Yosemite’s investment strategy?

Yosemite invests in a broad range of companies focused on cancer treatment, from early-stage research to drug development, utilizing both traditional venture capital investments and direct grants to scientists.

How does Yosemite differentiate itself from other venture capital firms?

Yosemite combines venture capital investments with philanthropic grants, aiming to support scientific breakthroughs at all stages of development and address the funding gap between discovery and commercialization.

Given the rapid advancements in cancer treatment and the increasing role of innovative technologies like AI and gene therapy, what impact might firms like Yosemite have on the future of oncology?